Developmental Funds

行政资金：项目摘要 Siteman癌症中心（SCC）的Siteman投资计划（SIP）包括一系列资助机制 通过有竞争力的资助机会支持创新的科学研究; 社区，流域和教师;和战略招聘工作，以加强和多样化SCC的科学 研究组合。SCC目前的五年战略计划以及SCC集水区的需求， 所有资金决策的基础。SCC高级领导层（SL）设计了SIP，以便与他们的 该中心的总体愿景，最优先考虑促进跨学科，翻译， 合作研究。 从癌症中心支持补助金（CCSG）发展基金部分获得的资金是 SCC慈善资产大幅增加，每年向SCC提供约400万美元（400万美元） 成员通过SIP研究发展奖（RDA）一年两次的资助机会。SCC SL设计 SIP RDA包括一个严格的同行评审过程，模仿NIH的评审过程。SCC SL和SCC 行政部门密切监测计划的进展和生产力，包括初级参与 investigators.自2015年以来，24名Pre-R01获奖者（42%）是初级研究人员，他们总共获得了450万美元 SIP RDA资金。在这24家公司中，有11家（46%）已经利用了至少一个外部奖项， 总计1350万美元SIP RDA计划还包括为没有资金的申请人提供指导机会， 包括初级教师，会见SIP RDA主席，讨论批评和改进结束时， 审查周期。重新提交的成功率为37%，这表明这些会议对以下方面很有价值： 未获得资助的SIP RDA申请人在未来的资助周期中重新申请。 从2013年到2017年，SCC通过SIP向所有七个SCC的调查人员颁发了总计2360万美元的奖金。 研究项目。到目前为止，SCC教师已经利用了1.2亿美元的直接成本（1.73亿美元的总成本），在外部 经费这1.2亿美元包括44个NCI奖项（8350万美元，总杠杆的70%）和31个NIH和其他癌症 同行评审赠款（2850万美元，占杠杆总额的23%）;因此，SIP杠杆总额的93%来自 来自同行评审的奖项。在下一个项目期间，SCC将增加对SIP的承诺和投资 通过支持新颖和合作研究，显著推进癌症发现， 投资于教师招聘，并为资金不足和/或资金不足的研究人员提供资金- 启动临床试验。CCSG发展基金的资助将继续授予SCC成员 通过SIP RDA计划。

DEVELOPMENTAL FUNDS: PROJECT SUMMARY Siteman Cancer Center’s (SCC’s) Siteman Investment Program (SIP) includes a portfolio of funding mechanisms that support innovative scientific research through competitive funding opportunities; investments in our community, catchment, and faculty; and strategic recruitment efforts to strengthen and diversify SCC’s scientific research portfolio. SCC’s current five-year strategic plan, as well as the needs of SCC’s catchment area, provide the foundation for all funding decisions. SCC Senior Leadership (SL) designed the SIP to align closely with their overall vision for the center, with the highest priority placed on promotion of transdisciplinary, translational, and collaborative research. Funding received from the Cancer Center Support Grant (CCSG) Developmental Funds component is significantly augmented by SCC philanthropic assets to provide approximately $4 million ($4M) per year to SCC members through the SIP Research Development Award (RDA) biannual funding opportunity. SCC SL designed SIP RDA to include a rigorous peer-review process modeled after the NIH review process. SCC SL and SCC Administration closely monitor program outcomes for progress and productivity, including participation by junior investigators. Since 2015, 24 Pre-R01 awardees (42%) were junior investigators who collectively received $4.5M in SIP RDA funding. Of those 24, 11 (46%) have already leveraged at least one external award, collectively totaling $13.5M in directs. The SIP RDA program also includes a mentoring opportunity for unfunded applicants, including junior faculty, to meet with the SIP RDA chair to discuss critiques and improvements at the end of the review cycle. The success rate for resubmissions is 37%, which suggests that these meetings are valuable for unfunded SIP RDA applicants who reapply in future funding cycles. From 2013–2017, SCC awarded a total of $23.6M through the SIP to investigators across all seven of SCC’s research programs. To date, SCC faculty have leveraged $120M in direct costs ($173M total costs) in external funding. This $120M includes 44 NCI awards ($83.5M, 70% of total leveraged) and 31 NIH and other cancer peer-reviewed grants ($28.5M, 23% of total leveraged); thus, 93% of all dollars leveraged from the SIP come from peer-reviewed awards. In the next project period, SCC will grow its commitment to and investment in SIP to significantly advance cancer discovery through support of novel and collaborative research, recurring annual investment for faculty recruitment, and by providing funding for unfunded and/or underfunded investigator- initiated clinical trials. Funding from CCSG Developmental Funds will continue to be awarded to SCC members through the SIP RDA program.